News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Public Health Emergency Surveillance System celebrates 20 years of service

Public Health Emergency Surveillance System celebrates 20 years of service

Indiana’s syndromic surveillance system for public health surpasses the typical lifespan of public health technical initiatives Created by Regenstrief

Kosali Simon, PhD

Research team to study critical aspects of Alzheimer’s and dementia healthcare delivery

Kosali Simon, PhD, M.A., a professor with the Paul H. O’Neill School of Public and Environmental Affairs and a

Sarah Wiehe, MD

Regenstrief researcher on author list for 1 of JAMA’s 2024 most viewed papers

A paper co-authored by Regenstrief Research Scientist Sarah Wiehe, M.D., M.P.H., as a member of the U.S. Preventive Services

Marianne Matthias, PhD

Study to address health inequities in chronic pain treatment moves to full clinical trial

INDIANAPOLIS – A successful pilot study to address health inequities related to chronic pain and depression has received notification